UNDERSTANDING RESPONSE AND RESISTANCE TO INHIBITION OF MUTANT ISOCITRATE DEHYDROGENASE IN ACUTE MYELOID LEUKAEMIA
Grant number: 1099160 | Funding period: 2016 - 2018
Acute myeloid leukaemia (AML) is an aggressive cancer of white blood cells and development of novel treatment options is urgently needed. Mutations in enzymes known as isocitrate dehydrogenase (IDH) -1 and -2 are amongst the most common in AML and recent studies strongly suggest that mutant IDH proteins are attractive drug targets. In this proposal we will use advanced genetic tools to comprehensively analyse the role of IDH dysfunction in leukaemia initiation, development and progression.